ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) Q3 2023 Earnings Conference Call March 16, 2023 10:30 AM ET
Company Participants
Jennifer Bath - CEO
Barry Duplantis - VP-Client Relations
Ilse Roodink - Chief Scientific Officer
Brad McConn - CFO
Conference Call Participants
Will McHale - Ingalls & Snyder
Swayampakula Ramakanth - H.C. Wainright
Michael Freeman - Raymond James
Operator
Good morning, and welcome to IPA's Earnings Call for the Third Quarter Fiscal Year 2023. I am Regina, and I will be your host for today's call.
Before we begin, I would like to remind everyone that our remarks today may include forward-looking statements, which are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in our statements. We encourage you to review our filings with the Securities and Exchange Commission for a more complete discussion of these risks and uncertainties. IPA undertakes no obligation to update these forward-looking statements, except as required by law.
On today's conference call and the accompanying presentation slides, non-GAAP financial measures will be used to help investors and analysts understand IPA's business performance. IPA believes adjusted EBITDA reflects the business in a manner that allows for a meaningful period-to-period comparisons and analysis of trends in its business. An explanation and reconciliation of non-GAAP to GAAP measures can be found in the text of our management discussion and analysis filed on EDGAR and SEDAR.
With that, I will now turn the call over to IPA's CEO, Dr. Jennifer Bath, to provide an overview of our results for the quarter.
Jennifer Bath
Thank you, Regina.
Ladies and gentlemen, welcome to our third quarter earnings call. We are happy to report a very noteworthy quarter for IPA, characterized by strong revenue growth, the expansion of new revenue streams using our AI-driven LENSai complex technology and the establishment of a potentially disruptive and valuable AI-driven research collaboration.
Regarding this most recent pioneering collaboration, the partnership aims to tackle some of the world's most challenging drug targets, specifically those within cells, which have been long considered inaccessible. By combining IPA's unique discovery technologies with Libera Bio's intracellular targeting formulations, we believe we are offering our investors an important value proposition.
Furthermore, we are energized by our ongoing efforts to finalize an AI-driven research collaboration on an additional complex oncology program. The partnership is under negotiation with a highly respected multibillion-dollar global leader in the field of oncology therapeutics and also focuses on a particularly challenging class of oncological proteins.